Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (September 2026)
24 slides from Sona Nanotech's investor presentation, September 2026
Slide 1: Turning Cold Tumors into Hot Opportunities
Sonic TURNING 5 = COLD TUMORS Ale mote ch: INTO HOT TARGETED SCIENCE. OPPORTUNITIES BIGGER POSSIBILITIES. afl Making Immunotherapy Cancer Drugs Work é For More Patients. = A The Clinical Promise of ‘THT’ eRe i SEPTEMBER 2026
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses activities this presentation due to risks and uncertainties affecting Sona or developments tha
Slide 3: Executive Summary
Executive Summary • 60-99% of patients fail today’s best cancer drugs, depending on the solid cancer type • Patients fail due to a lack of prior immune system engagement in fighting the cancer • Sona’s THT therapy effectively primed 8/10 biopsied tumors in patients who had failed on standard immunot
Slide 4: Cancer Immunotherapy Drugs Sell $120B+ Per Year
Cancer Immunotherapy Drugs Sell $120B+ Per Year Global immuno-oncology drug sales (USD Billions) m= $120B GLOBAL IMMUNO-ONCOLOGY DRUG MARKET IN 2025 et ~24% CAGR (2021-2030) Keytruda® Opdivo® (pembrolizumab) (nivolumab) 50 $31.7B | $10.0B 0 2025 global sales 2025 global sales 2021 2022 2023 2025 203
Slide 5: Why do the best immunotherapy drugs so seldom work?
5 Why do the best immunotherapy drugs so seldom work? 5 Source: JAMA Oncol . 2021 May 1;7(5):739-743.
Slide 6: The Immune System Can't Attack What It Can't See
The Immune System Can’t Attack What It Can’t See COLD TUMOR Invisible to the immune system T cell (immune cell) Cancer cell hiding fro the immune system The immune system does not recognize the cancer. _ _— > a so on ai _ Si When the immune system can’t see the cancer, there is little or no attack —
Slide 7: Source: JAMA Oncol. 2021
7 Source: JAMA Oncol . 2021 May 1;7(5):739-743.
Slide 8: How Can Tumor Antigens Be Elicited To Activate And Engage The Innate Immune System?
How Can Tumor Antigens Be Elicited To Activate And Engage The Innate Immune System? 8
Slide 9: Give me the power to produce fever, and I shall cure any disease
“Give me the power to produce fever, and I shall cure any disease.” The Father of Medicine Hippocrates 460-370 BCE 9
Slide 10: THT Converts Cold Melanoma Tumors Into Immune Responsive Ones
Targeted Hyperthermia Therapy (“THT”) Converts ‘Cold’ Melanoma Tumors Into Immune Responsive Ones 10 Engaging the immune system converts ‘cold’ tumors into ‘hot’ ones better enabling immunotherapies 10
Slide 11: Sona's Patented Gold Nanorods Heat Quickly And Are CTAB-free
Sona’s Patented Gold Nanorods Heat Quickly And Are CTAB-free So Ideal For In Vivo Nanomedical Applications Sona’s Gold Nanorod’s (“GNR”) Advantages Highly functional: • Optimal nanoparticle for thermal conversion • Can be ‘tuned’ to react to set wavelengths • Can be conjugated to molecules Uniquely
Slide 12: THT Involves In-clinic Injection Of Gold Nanorods Followed By Near Infrared Light
THT Involves In-clinic Injection Of Biocompatible Sona Gold Nanorods Into A Tumor Followed By A 5-10 Minute Application Of Near Infrared Light Step 1 - Intertumoral injection of 0.5ml Step 2 - Initiate and monitor GNR solution hyperthermia for 5-10 minutes 12
Slide 13: THT Cleared Select Cancer Tumors In Two Weeks, With Abscopal Effect
THT Cleared Select Cancer Tumors In Two Weeks, With Secondary, ‘Abscopal Effect’ Seen In Two Patients Day 1 - Pre-THT Day 16 - After THT x2 Tumors treated Abscopal effect seen as untreated tumors improved with THT 13
Slide 14: 38% of combination therapy cohort showed treatment durability to day 48
38% of combination therapy cohort showed treatment durability to day 48 14
Slide 15: Next Clinical Study To Combine THT With Immunotherapy
Next Clinical Study To Combine THT With Immunotherapy @& Patient fails immunotherapy | 1 THT treatment to ‘prime’ the tumor L ¥ A % Immunotherapy reintroduced A 15
Slide 16: In Summary, Sona's THT Approach
In Summary, Sona’s THT Approach: »> Make the cancer visible. v | Let the immune system attack it. v 9g Enable immunotherapy to amplify the attack. 16
Slide 17: Strategic Positioning: Different Routes. Same Destination.
STRATEGIC POSITIONING Different Routes. Same Destination. Moderna and Merck validated the principle. THT takes a different route to the same destination. PERSONALIZED & NEOANTIGEN VACCINES Patient-specific immune priming. ONCOLYTIC VIRUSES SZ xsiotocics Stimulate immune recognition. _ MORE PATIENTS
Slide 18: Melanoma Is The Proving Ground, But More Could Follow
Melanoma Is The Proving Ground, soma But More Could Follow “ae Sona’s Product Pipeline — By Stage Of Development PROGRAM eee INDICATION! || Couceey econ Pee reee) el ceca? PILOT PIVOTAL | APPROVED Melanoma Stage II/III/IV =a Breast Cancer k= Colorectal I THT Oral Cancer | Solid Tumor Squamous = Ther
Slide 19: Sona's THT Therapy Is Proprietary And Benefits From IP Protection
Sona’s THT Therapy Is Proprietary And Benefits From IP Protection Sond Patents e Method for manufacture of biocompatible gold nanorods © Issued: USA, Canada and South Korea © Pending: PCT, EU © Photothermal Near-Infrared LED light device © Issued Dec. 11, 2014, as US Patent #10,064,940 * Gold nanopa
Slide 20: Sona's Team Hits Above The Company's Weight
Sona’s Team Hits Above The Company’s Weight song “nanotech» Board Mark Lievonen, C.M. Walter Straps, PhD Neil Fraser, P.Eng., MBA Jim Megann Wayne Myles, KC Len Pagliaro, PhD Michael Fleming, MBA Chairman Director Director Director Director Director . Feira Led vaccine maker ® CSO of Khosla Ventures
Slide 21: Path Forward
Path Forward 1. Publish first-in-human results showing THT alone priming tumors • Peer review pending 2. Combination clinical study expected to start this fall • THT plus immunotherapy for late-stage melanoma to assess durability 3. Full clinical trial in Canada expected to start in 2027 • Health Ca
Slide 22: Capitalization Table
Capitalization Table As of September 16, 2026 Market Capitalization Share Price C$0.37 Market Cap. C$42M (US $30M) gz Capital Structure Issued & Outstanding 122.8M Options 8.0M Warrants 367k Ownership > Sona -nanotech:) Board and Management @ Public
Slide 23: Sona's Mission
Sona’s Mission: No Immunotherap Patient Left Behin = 5 © = POTENTIALLY POTENTIALLY POTENTIALLY FASTER SIMPLER LESS EXPENSIVE uy
Slide 24: David Regan, CEO
David Regan BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY CEO [email protected] +1 902 448 1416 www.sonanano.com OTCQB: SNANF | CSE: SONA 24
Sona Nanotech — Investor Presentation (September 2026) on 6ix